Intellia Therapeutics, Inc. (NTLA)

NASDAQ: NTLA · USD

$13.3

+1.05 (+8.6%)· Recorded snapshot

Market cap	1.9B
Revenue (ttm)	59.5M
Net income (ttm)	-400M
EPS (ttm)	-$3.34
Shares out	140.1M
Volume	4,236,745
Beta	1.80

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 59.5M
Net income (ttm): -400M
EPS (ttm): -$3.34
Market cap: 1.9B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Держать

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-55.4

P25 -113.8P50 -46.5P75 -0.9

ROIC-32.7

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All NTLA indicators

Market & fundamental data

Available fields

201

Groups with data

Currency

USD

Showing 201 of 201 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001652130
Company name	Intellia Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	45826J105
Earnings date	2026-11-09
Earnings time	bmo
Employees	377
Employees change	-26
Employees growth	-6.45%
Enterprise value	$1.3B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2014
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2016-05-06
Is primary listing	Yes
Is SPAC	No
ISIN number	US45826J1051
Last 10-K release date	2026-02-26
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$1.9B
Market cap category	Small-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$13.33
Price currency	USD
Sector	Healthcare
SIC code	2835
Stock price date	2026-10-28
Symbol	NTLA
U.S. state	Massachusetts
Website	https://www.intelliatx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-25.09%
EV/Sales	21.08x
FCF / EV yield	-27.8%
FCF yield	-19.27%
Forward EV/Sales	23.26x
Forward P/S	33.55x
P/B ratio	2.36x
P/S ratio	30.4x
Price / tangible book value	2.49x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Operating margin	-711.66%
Pretax margin	-672.16%
Profit per employee	$-1.1M
Revenue per employee	$157,841
ROA	-30.14%
ROA (5Y)	-22.82%
ROCE	-54.45%
ROE	-55.44%
ROE (5Y)	-45.09%
ROIC	-32.7%
SBC / revenue	114.1%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	8
EPS growth years	3
Net income growth years	1
Revenue growth	12.58%
Revenue growth (Q)	-46.23%
Revenue growth (QoQ)	-49.1%
Revenue growth 10Y	20.31%
Revenue growth 3Y	3.91%
Revenue growth 5Y	7.31%
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-2M
Depreciation and amortization	$9.1M
EBIT	$-423.5M
EBITDA	$-414.4M
EPS	$-3.34
FCF per share	$-2.49
Financing cash flow	$346.5M
Free cash flow	$-348.7M
Free cash flow minus SBC	$-416.6M
Gross profit	$-222.8M
Investing cash flow	$-48.5M
Net cash flow	$-48.6M
Net income	$-400M
Operating cash flow minus SBC	$-414.5M
Operating income	$-423.5M
Revenue	$59.5M
Stock-based compensation	$67.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	1.65
Book value per share	$5.20
Debt / equity	0.1
Long-term assets	$329.3M
Long-term liabilities	$50.1M
Net cash (debt)	$554.9M
Net cash / market cap	30.68%
Net cash growth	5.12%
Net debt / equity	-0.76
Piotroski F-Score	4
Property, plant and equipment	$101M
Shareholders' equity	$727.7M
Tangible book value	$727.7M
Tangible book value per share	$5.20
Total assets	$857.2M
Total cash	$437.8M
Total debt	$73.4M
Total liabilities	$129.5M
WACC	13.6%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.07
Current assets	$527.8M
Current liabilities	$79.4M
Current ratio	6.65
Net working capital	$34M
Quick ratio	5.61
Working capital	$448.4M
Working capital turnover	0.14

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-16.64%
Dividend yield	0%
Shareholder yield	-16.64%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	3.33%
10Y return CAGR	0.33%
10Y total return	3.33%
150-day SMA	$13.05
1D price change	8.55%
1M price change	13.45%
1M total return	13.45%
1W price change	14.42%
1W total return	14.42%
1Y price change	-9.87%
1Y return CAGR	-9.88%
1Y total return	-9.87%
20-day SMA	$11.99
200-day SMA	$13.07
3M price change	24.93%
3M total return	24.93%
3Y price change	-42.44%
3Y return CAGR	-16.81%
3Y total return	-42.44%
50-day SMA	$12.23
50-day SMA vs 200-day SMA	50under200
52-week high	$18.48
52-week high date	2026-07-02
52-week low	$7.95
52-week low date	2025-11-21
5Y price change	-89.71%
5Y return CAGR	-36.55%
5Y total return	-89.71%
6M price change	2.22%
6M total return	2.22%
All-time high	$202.73
All-time high date	2021-06-30
All-time low	$5.90
All-time low date	2025-04-07
Average true range (ATR)	$0.77
Average volume	5.6M
Beta (1Y)	2.15
Beta (2Y)	1.99
Beta (5Y)	1.8
Change from 52-week high	-27.87%
Change from 52-week low	67.67%
Change from all-time high	-93.42%
Change from all-time low	125.93%
Change from open	10.53%
Day's gap	-1.79%
Dollar volume	$56.5M
High price	$13.33
Low price	$12.00
Monthly RSI	46.07
Open price	$12.06
Position in 52-week range	100%
Premarket change	-1.55%
Premarket close	$12.28
Premarket price	$12.09
Premarket volume	11K
Previous close	$12.28
Price vs 150-day SMA	2.12%
Price vs 20-day SMA	11.14%
Price vs 200-day SMA	1.98%
Price vs 50-day SMA	8.97%
Relative volume	0.76
RSI	62.76
Sharpe ratio	0.22
Sharpe ratio (3Y)	0.1
Sharpe ratio (5Y)	-0.23
Sortino ratio	0.39
Sortino ratio (3Y)	0.2
Sortino ratio (5Y)	-0.26
Volume	4.2M
Weekly RSI	53.31
YTD price change	48.28%
YTD total return	48.28%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	134.2M
Float percentage	95.78%
Shares change (QoQ)	12.65%
Shares change (YoY)	16.64%
Shares held by insiders	1.58%
Shares held by institutions	99.5%
Shares outstanding	140.1M
Short % of float	33.11%
Short % of shares	31.71%
Short ratio	11.1 days

Deeper analysis on NTLA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this NTLA report

Is a complete NTLA research report available?

No complete published report is available for Intellia Therapeutics, Inc. (NTLA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Intellia Therapeutics, Inc. (NTLA)

Price

Financial snapshot

Fair-value bridge

Latest news · NTLA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NTLA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on NTLA

Frequently asked questions